Skip to main content
. 2020 Sep 12;20(6):571–590. doi: 10.1007/s40256-020-00439-5
Original, observational (prospective or retrospective) studies
Included patients with coronavirus disease 2019 (COVID-19)
Documented use of either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)
Reported frequency, percentage, and/or adjusted estimate of mortality or disease severity and/or adverse clinical outcomes (septic shock, admission to intensive care units) associated with COVID-19
From any region or language